Published: 15 June 2024
Author(s): R. Solans-Laqué, I. Rúa-Figueroa, M. Blanco Aparicio, I. García Moguel, R. Blanco, F. Pérez Grimaldi, A. Noblejas Mozo, M. Labrador Horrillo, J.M. Álvaro-Gracia, C. Domingo Ribas, G. Espigol-Frigolé, F. Sánchez-Toril López, F.M. Ortiz Sanjuán, E. Arismendi, M.C. Cid
Section: Original Article

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome [1], is a systemic vasculitis classified as an anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) [1–3]. EGPA is a rare disease with an annual global incidence rate of 1.7 cases per million people per year and a prevalence of 15.6 cases per million people [4]. It arises during the 4th to 6th decade of life, with an average age at diagnosis of 49 years, although paediatric cases have also been reported.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.